David Thompson
Corporate Officer/Principal bei INOZYME PHARMA, INC.
Aktive Positionen von David Thompson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 01.07.2021 | - |
Karriereverlauf von David Thompson
Ehemalige bekannte Positionen von David Thompson
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| INOZYME PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2018 | 13.10.2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Gründer | - | - |
| Präsident | - | - |
Ausbildung von David Thompson
| University of Connecticut | Doctorate Degree |
| The University of Montana | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Graduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Börse
- Insiders
- David Thompson
- Erfahrung
